Hou W, Arita Y, Morisset J
Département de Médecine, Faculté de Médecine, Université de Sherbrooke, Quebec, Canada.
Am J Physiol. 1996 Nov;271(5 Pt 1):C1735-42. doi: 10.1152/ajpcell.1996.271.5.C1735.
This study was performed to evaluate the effect of caerulein, a cholecystokinin analogue, on arachidonic acid (AA) release in rat pancreatic acini and to determine the cellular mechanism involved. Caerulein did not stimulate phospholipase A2 (PLA2); however, diacylglycerol (DAG) lipase activity was increased. Validity of PLA2 or DAG lipase inhibitors was confirmed by their ability to selectively inhibit PLA2 or DAG lipase activities. Caerulein increased AA release from acini prelabeled with [3H]AA both dose and time dependently. Inhibitors were used to evaluate the involvement of different signaling pathways. Mepacrine and aristolochic acid, two PLA2 inhibitors, did not inhibit caerulein-induced AA release, whereas the DAG lipase inhibitor RHC-80267 did. The phospholipase C (PLC) inhibitor U-73122 totally inhibited caerulein-induced AA release, whereas the phospholipase D (PLD) inhibitor wortmannin had no effect. Our data indicate that caerulein-induced AA release results from the combined action of PLC and DAG lipase without PLA2 or PLD activation.
本研究旨在评估胆囊收缩素类似物蛙皮素对大鼠胰腺腺泡中花生四烯酸(AA)释放的影响,并确定其中涉及的细胞机制。蛙皮素不刺激磷脂酶A2(PLA2);然而,二酰基甘油(DAG)脂肪酶活性增加。PLA2或DAG脂肪酶抑制剂的有效性通过其选择性抑制PLA2或DAG脂肪酶活性的能力得到证实。蛙皮素剂量和时间依赖性地增加了用[3H]AA预标记的腺泡中AA的释放。使用抑制剂来评估不同信号通路的参与情况。两种PLA2抑制剂美帕林和马兜铃酸不抑制蛙皮素诱导的AA释放,而DAG脂肪酶抑制剂RHC-80267则抑制。磷脂酶C(PLC)抑制剂U-73122完全抑制蛙皮素诱导的AA释放,而磷脂酶D(PLD)抑制剂渥曼青霉素则无作用。我们的数据表明,蛙皮素诱导的AA释放是PLC和DAG脂肪酶共同作用的结果,而不涉及PLA2或PLD的激活。